Artivion, Inc.
Description
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
About
CEO
Mr. James Patrick Mackin
Employees
1,500
Instrument type
Common Stock
Sector
Healthcare
Industry
Medical Devices
MIC code
XNYS
Address
1655 Roberts Boulevard N.W., Kennesaw, GA 30144, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 5, 2025 | — | — | — | — |
| Aug 7, 2025 | — | — | — | — |
| May 5, 2025 | — | — | — | — |
| Feb 13, 2025 | -0.01 | — | — | — |
| Nov 8, 2024 | -0.06 | -0.05 | 0.01 | -16.67% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 3 | — | 4 |
| Average estimate | — | 0.08 | — | 0.48 |
| Low estimate | — | 0.04 | — | 0.42 |
| High estimate | — | 0.11 | — | 0.55 |
| Last year EPS | — | 0.06 | — | 0.29 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-65.910%
Next qtr. (Mar 2025)
33.330%
Current year
45.000%
Next year (Dec 2025)
63.790%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 354.00M | 313.79M | 298.84M | 253.23M | 276.22M |
| Cost of revenue | 124.83M | 111.27M | 101.32M | 85.44M | 93.21M |
| Gross profit | 229.18M | 202.52M | 197.51M | 167.78M | 183.01M |
| Operating expense | |||||
| Research & development | 28.71M | 38.88M | 35.55M | 24.21M | 22.96M |
| Selling general and admin | 208.98M | 157.44M | 169.77M | 141.14M | 143.01M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -8.51M | 6.20M | -7.81M | 2.44M | 17.04M |
| Non operating interest income | |||||
| Income | 1.08M | 147,000 | 79,000 | 217,000 | 738,000 |
| Expense | 25.30M | 18.22M | 16.89M | 16.70M | 14.89M |
| Other income expense | 11.14M | -3.11M | 9.79M | -3.13M | -1.25M |
| Pretax income | -21.59M | -14.98M | -14.83M | -17.17M | 1.64M |
| Tax provision | 9.10M | 4.21M | 7,000 | -492,000 | -76,000 |
| Net income | -30.69M | -19.19M | -14.83M | -16.68M | 1.72M |
| Basic EPS | -0.75 | -0.48 | -0.38 | -0.44 | 0.05 |
| Diluted EPS | -0.75 | -0.48 | -0.38 | -0.44 | 0.05 |
| Basic average shares | 40.74M | 40.03M | 38.98M | 37.86M | 37.12M |
| Diluted average shares | 40.74M | 40.03M | 38.98M | 37.86M | 37.12M |
| EBITDA | 12.54M | 25.68M | 10.11M | 20.24M | 34.85M |
| Net income from continuing op. | -30.69M | -19.19M | -14.83M | -16.68M | 1.72M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | -123,000 | -98,000 | -94,000 | -111,000 | 12,000 |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 792.40M | 762.80M | 793.05M | 789.40M | 605.65M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 58.94M | 39.35M | 55.01M | 61.41M | 33.77M |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | 71.80M | 61.82M | 53.02M | 45.96M | 52.94M |
| Other receivables | 2.34M | 7.76M | 5.09M | 2.79M | 2.92M |
| Inventory | 81.98M | 74.48M | 76.97M | 73.04M | 53.07M |
| Prepaid assets | — | — | 14.75M | 14.30M | 11.61M |
| Restricted cash | — | — | — | 546,000 | 528,000 |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 15.81M | 17.55M | 14.75M | — | — |
| Non current assets | |||||
| Properties | 43.82M | 41.86M | 58.10M | 28.24M | 27.01M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 74.17M | 79.63M | 80.49M | 72.33M | 66.92M |
| Construction in progress | — | — | — | — | — |
| Leases | 49.11M | 47.38M | 39.18M | 38.26M | 36.17M |
| Accumulated depreciation | -84.92M | -88.34M | -94.53M | -87.18M | -75.96M |
| Goodwill | 666.91M | 669.91M | 701.50M | 747.18M | 531.13M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 172.23M | 182.65M | 201.50M | 227.06M | 157.73M |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 9.98M | 8.65M | 10.62M | 16.05M | 19.69M |
| Total liabilities | 510.62M | 478.47M | 492.32M | 460.69M | 319.96M |
| Current liabilities | |||||
| Accounts payable | 13.32M | 12.00M | 10.40M | 9.62M | 9.80M |
| Accrued expenses | 14.17M | 14.49M | 11.38M | 11.09M | 11.10M |
| Short term debt | 5.43M | 5.43M | 5.31M | 7.57M | 7.25M |
| Deferred revenue | — | — | — | — | — |
| Tax payable | 3.84M | 2.64M | 3.63M | 2.81M | 2.98M |
| Pensions | 18.72M | 13.81M | 13.16M | 10.19M | 12.26M |
| Other current liabilities | 2.39M | 1.31M | 1.08M | 19.18M | 1.81M |
| Non current liabilities | |||||
| Long term debt | 352.91M | 351.40M | 356.74M | 309.80M | 237.90M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | 21.85M | 24.50M | 28.80M | 34.71M | 25.84M |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 71.23M | 47.43M | 55.88M | 50.19M | 6.58M |
| Shareholders equity | |||||
| Common stock | 426,000 | 418,000 | 414,000 | 404,000 | 390,000 |
| Retained earnings | -47.91M | -17.22M | 1.98M | 20.02M | 36.70M |
| Other shareholders equity | -12.01M | -21.61M | -9.89M | 6.74M | -8.59M |
| Total shareholders equity | 281.78M | 284.33M | 300.73M | 328.71M | 285.70M |
| Additional paid in capital | 355.92M | 337.39M | 322.87M | 316.19M | 271.78M |
| Treasury stock | 14.65M | 14.65M | 14.65M | 14.65M | 14.59M |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||||||||||||
| Net Income | -30.69M | -19.19M | -14.83M | -16.68M | 1.72M | -2.84M | 3.70M | 10.78M | 4.01M | 7.32M | 16.17M | 7.95M | 7.37M | 3.94M | 8.68M | 31.95M | 7.20M | 365,000 | -19.54M | -18.75M | -32.29M | -27.76M | 9.17M | 7.82M | 4.45M | 6.50M | 4.70M | 3.90M | 2.20M | 1.30M | 600,000 | 700,000 | -700,000 |
| Depreciation | 23.08M | 22.44M | 23.98M | 20.71M | 18.32M | 18.10M | 9.75M | 8.38M | 5.86M | 6.03M | 5.84M | 5.63M | 4.96M | 3.94M | 4.26M | 4.35M | 4.46M | 4.84M | 5.04M | 5.48M | 5.51M | 5.42M | 4.61M | 3.22M | 3.15M | 3.50M | 2.70M | 1.40M | 1.00M | 1.00M | 700,000 | 700,000 | 600,000 |
| Deferred Taxes | -1.39M | -1.72M | -4.47M | 4.28M | -2.31M | -4.49M | -1.48M | 595,000 | 3.68M | 178,000 | 617,000 | 1.23M | 1.77M | -1.51M | 5.25M | -7,000 | -961,000 | 226,000 | — | — | 5.73M | -5.57M | 624,000 | 1.66M | -970,000 | -1.90M | 400,000 | 200,000 | -100,000 | -200,000 | — | — | — |
| Stock-Based Compensation | 14.42M | 12.34M | 10.71M | 6.91M | 8.80M | 6.33M | 6.92M | 6.33M | 5.09M | 3.44M | 3.24M | 3.16M | 2.79M | 2.62M | 2.43M | 2.10M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | 39.06M | 2.53M | 20.87M | 20.40M | 7.19M | 2.15M | 676,000 | 268,000 | 268,000 | -474,000 | 298,000 | 683,000 | 767,000 | 3.70M | 676,000 | -17.34M | 3.71M | 3.35M | 3.81M | -3.39M | -2.44M | 1.42M | 348,000 | — | — | -100,000 | 100,000 | — | -200,000 | 100,000 | -200,000 | — | — |
| Accounts Receivable | -4.05M | -13.34M | -11.56M | 9.94M | -5.33M | -1.12M | -7.26M | 4.14M | -3.81M | -4.56M | -1.64M | 1.36M | -2.23M | 179,000 | -745,000 | -785,000 | -23,000 | -2.22M | -830,000 | -2.16M | 954,000 | 7.08M | -2.71M | 469,000 | -1.71M | -1.80M | -500,000 | -2.60M | -1.80M | -200,000 | -800,000 | -300,000 | -1.50M |
| Accounts Payable | 1.68M | -1.96M | -1.89M | -9.16M | 251,000 | -8.87M | 8.73M | 4.72M | -656,000 | -64,000 | 572,000 | 529,000 | -772,000 | 2.38M | — | 267,000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -14.36M | -8.40M | -18.38M | -24.76M | -16.25M | 4.77M | -18.74M | -18.92M | -4.52M | -2.26M | 386,000 | -3.20M | 4.89M | 11.10M | -1.14M | -19.49M | -6.75M | -18.42M | -12.33M | -10.02M | 6.46M | -22.54M | -3.34M | -4.60M | -4.44M | -5.10M | -6.80M | -1.10M | 400,000 | 800,000 | -2.80M | -900,000 | -1.20M |
| Operating Cash Flow | 27.76M | -7.29M | 4.42M | 11.65M | 12.39M | 14.02M | 2.29M | 16.30M | 9.92M | 9.61M | 25.49M | 17.35M | 19.54M | 26.34M | 19.42M | 1.05M | 7.64M | -11.85M | -23.85M | -28.83M | -16.09M | -41.95M | 8.70M | 8.57M | 485,000 | 1.10M | 600,000 | 1.80M | 1.50M | 2.80M | -2.50M | 200,000 | -2.80M |
| Investing Activities | |||||||||||||||||||||||||||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -1.19M | -1.63M | -977,000 | -924,000 | 138,000 | -4.10M | -14.33M | -9.49M | -3.85M | 8.30M | -5.10M | -8.50M | -1.60M | -1.30M | -800,000 | -700,000 | -600,000 |
| Net Intangibles | — | -1.70M | -972,000 | — | — | — | -409,000 | -1.23M | -613,000 | -1.01M | -196,000 | -819,000 | — | -5.41M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | -5.00M | — | — | -64.12M | -15.00M | — | -163.92M | -71.36M | -1.35M | — | — | -17.04M | -21.06M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | — | — | — | — | — | — | — | — | — | — | — | — | -3.57M | -2.41M | -3.04M | -6.12M | -12.33M | -17.39M | -21.69M | -563,000 | -15.43M | -23.17M | -29.34M | -5.73M | -5.12M | -34.30M | — | — | -2.20M | -100,000 | -3.70M | — | — |
| Sale of Investments | — | — | 19.00M | — | — | — | 1.01M | 1.07M | 2.05M | 1.17M | 15.42M | — | — | — | 1.13M | 3.57M | 14.16M | 18.56M | 20.84M | 2.00M | 30.89M | 28.31M | 24.24M | 8.54M | 6.15M | 7.80M | — | 5.90M | — | — | — | — | — |
| Investing Cash Flow | 6.93M | -1.70M | 19.72M | -65.80M | -15.87M | -929,000 | -163.00M | -70.42M | -996,000 | -1.04M | 15.41M | -19.03M | -28.75M | -5.61M | -2.69M | -2.60M | 446,000 | -557,000 | -2.03M | 457,000 | 15.75M | -394,000 | -18.10M | -6.64M | -3.28M | -18.90M | -9.60M | -4.20M | -4.80M | -1.40M | -4.50M | -700,000 | -600,000 |
| Financing Activities | |||||||||||||||||||||||||||||||||
| Long-Term Debt Issuance | — | — | — | 100.00M | — | — | 225.00M | 75.00M | — | — | — | — | — | — | 1.27M | 1.73M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | -5.30M | -2.75M | -3.09M | -35.35M | -2.78M | -2.79M | -72.21M | -1.41M | — | — | — | — | -31,000 | -1.54M | -1.33M | -5.93M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | 2.77M | -459,000 | -10.98M | -1.48M | -728,000 | -1.53M | -11.05M | -1.67M | 458,000 | 738,000 | -87,000 | -143,000 | -476,000 | 2.45M | 1.27M | 1.30M | — | 2.35M | — | — | — | — | — | 360,000 | — | 100,000 | — | — | — | — | -100,000 | -100,000 | 100,000 |
| Financing Cash Flow | -5.62M | -5.01M | -15.98M | 61.18M | -6.25M | -6.42M | 140.12M | 71.23M | -4.34M | -9.63M | -5.26M | -5.05M | -3.60M | -6.18M | -442,000 | -4.86M | 784,000 | 1.79M | 18.94M | 19.65M | 660,000 | 809,000 | 1.50M | 1.41M | -3.73M | 43.00M | 600,000 | 600,000 | 300,000 | 100,000 | 8.80M | — | 4.00M |
| Other Cash Details | |||||||||||||||||||||||||||||||||
| End Cash Position | 58.94M | 39.35M | 55.01M | 61.96M | 34.29M | 42.24M | 40.75M | 57.34M | 37.59M | 33.38M | 37.64M | 13.01M | 21.71M | 35.50M | 30.12M | 17.20M | 14.46M | 4.13M | 6.63M | 4.71M | 4.90M | 3.10M | 7.20M | 17.48M | 6.13M | 12.90M | — | — | — | — | — | — | — |
| Income Tax Paid | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 11.40M | -14.17M | -16.65M | 5.04M | 7.76M | 4.10M | 3.76M | 12.30M | 7.95M | 3.81M | 12.24M | 15.10M | 14.21M | 13.31M | 14.88M | 7.80M | 8.09M | -2.71M | -19.51M | -20.56M | -9.33M | -6.21M | -7.85M | 788,000 | -2.87M | -5.50M | -7.30M | -5.30M | 800,000 | 1.20M | -2.80M | -700,000 | -2.90M |
Error: Invalid format in Holders JSON file.
Article
On The Hunt For Magnificent Earnings Growth? Check These 7 Stocks.
None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
Feb 3, 2025
Article
Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 61st Society of Thoracic Surgery Annual Meeting
Full IDE Data Set Demonstrates Sustained Benefit at One Year with Use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion ATLANTA , Jan. 27, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from the AMDS PERSEVERE clinical trial (the "IDE") was presented in a Late-Breaking Science presentation at the 61st Annual Meeting of the Society of Thoracic Surgeons in Los Angeles, California. The data presented analyzed clinical outcomes across the full 93 study participant IDE cohort at one year following AMDS implantation.
Jan 27, 2025
Article
Best Momentum Stocks to Buy for January 7th
NN, VERX and AORT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 7, 2024.
Jan 7, 2025
